Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

25 Oct 2016 17:43

RNS Number : 4431N
GW Pharmaceuticals PLC
25 October 2016
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Julian Gangolli

2.

Reason for the notification

a.

Position/status

Director/President, US

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

 

c.

Price(s) and volume(s)

 

Price(s)

 0.1p

Volume(s)

10,608

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

 London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

301

 

ADS's issued upon conversion of 3,612 Ordinary shares

d.

Aggregated information

·Aggregated volume

·Price

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

 

American Depositary Shares

ISIN: 36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

 

Price(s)

 $120.75

Volume(s)

301

 

ADS's sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary Share and Restricted American Depositary Shares

Ordinary Shares: ISIN: GB0030544687

Restricted American Depositary shares: ISIN: US36197T1372

b.

Nature of the transaction

Conversion of Ordinary Shares into Restricted American Depositary shares (12 to 1 Conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

583

Restricted ADSs issued upon conversion of 6,996 Ordinary Shares

d.

Aggregated information

·Aggregated volume

·Price

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Christopher Tovey

2.

Reason for the notification

a.

Position/status

Director/Chief Operations Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

c.

Price(s) and volume(s)

 

Price(s)

 0.1p

Volume(s)

266,557

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

 London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

22,213

ADS's issued upon conversion of 266,556 Ordinary shares

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

American Depositary Shares

ISIN: US36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

 

Price(s)

 $120.36

Volume(s)

22,213

 

ADS's sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Geoffrey Guy

2.

Reason for the notification

a.

Position/status

Director/Chairman of the Board

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.43p

Volume(s)

206,100

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

21 October 2016

f.

Place of the transaction

 AIM, London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

 Ordinary Shares: ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.24

Volume(s)

68,900

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

AIM, London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

0.1 Pence Ordinary Shares

ISIN:GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.09

Volume(s)

125,000

 

Ordinary Shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

AIM, London

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Stephen Wright

2.

Reason for the notification

a.

Position/status

Director/Chief Medical Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares by the wife of Dr Stephen Wright

c.

Price(s) and volume(s)

 

Price(s)

 £8.10p

Volume(s)

1,556

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

 AIM, London

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFSRIILEFIR
Date   Source Headline
10th May 20134:24 pmRNSHolding(s) in Company
9th May 20133:40 pmRNSTotal Voting Rights
8th May 20138:00 amRNSClosing of Initial Public Offering on Nasdaq
7th May 20137:00 amRNSSativex Commercialization Approval in Italy
1st May 20135:47 pmRNSPricing of U.S. Initial Public Offering
22nd Apr 20137:00 amRNSUS Patent Allowance for SATIVEX Formulation Spray
18th Apr 20132:23 pmRNSAmendment to Registration Statement for NASDAQ
12th Apr 201310:31 amRNSResults of General Meeting
10th Apr 20137:00 amRNSSativex moved to Schedule 4 of UK Drugs Act
3rd Apr 20137:00 amRNSNew US Patent Allowance for Delivery of SATIVEX
22nd Mar 20132:35 pmRNSPosting of Shareholder Circular
19th Mar 20132:46 pmRNSAppoints Stephen Schultz VP of Investor Relations
19th Mar 20131:10 pmRNSUpdate on Sativex in Germany
19th Mar 20131:01 pmRNSFiling for listing on NASDAQ
19th Feb 20133:16 pmRNSDirectorate Change
19th Feb 20139:30 amRNSBlocklisting Interim Review
4th Dec 201210:04 amRNSDirector/PDMR Shareholding
30th Nov 20122:54 pmRNSDirector/PDMR Shareholding
30th Nov 20122:50 pmRNSDirector/PDMR Shareholding
28th Nov 20127:00 amRNSPreliminary Results
28th Nov 20127:00 amRNSPhIIa Study Identifies New Anti-Diabetic Treatment
22nd Nov 201211:31 amRNSNotice of Results
12th Nov 20127:00 amRNSGW to Present at Lazard Healthcare Conference
12th Oct 20127:00 amRNSPositive German Sativex Data Presented at ECTRIMS
1st Oct 20127:00 amRNSAppointment of Chief Operating Officer
13th Sep 20127:00 amRNSPublication of New Epilepsy Data
20th Aug 201212:14 pmRNSDirector/PDMR Shareholding
17th Aug 20124:04 pmRNSBlocklisting Interim Review
22nd Jun 20127:00 amRNSGerman GBA establishes positive benefit of Sativex
13th Jun 201210:19 amRNSDirector/PDMR Shareholding
6th Jun 20124:03 pmRNSDirector/PDMR Shareholding
23rd May 20123:56 pmRNSDirector/PDMR Shareholding
22nd May 20127:00 amRNSThird Cancer Pain Trial Commences
22nd May 20127:00 amRNSInterim Results
8th May 20127:00 amRNSSuccessful completion of MRP for Sativex
26th Apr 201211:00 amRNSNotice of Results
23rd Apr 20127:00 amRNSSativex phase IIb pain trial results publication
16th Apr 20127:00 amRNSAlmirall Milestone
5th Apr 20127:00 amRNSBoard Changes
2nd Apr 20122:31 pmRNSDirector/PDMR Shareholding
30th Mar 20121:57 pmRNSDirector/PDMR Shareholding
15th Mar 20127:00 amRNSGW and Almirall Strengthen Strategic Collaboration
8th Mar 20127:00 amRNSAppointment of Professor Vincenzo Di Marzo
17th Feb 20127:00 amRNSBlocklisting Interim Review
7th Feb 20127:00 amRNSSATIVEX® Regulatory Approval Received in Austria
25th Jan 20121:46 pmRNSResult of AGM
11th Jan 201211:43 amRNSHolding(s) in Company
11th Jan 201211:42 amRNSHolding(s) in Company
28th Dec 201110:39 amRNSDirector/PDMR Shareholding
22nd Dec 20117:00 amRNSSativex Approval in Sweden

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.